Amphotericin B and Itraconazole for Treatment of DisseminatedPenicillium marneffeiInfection in Human Immunodeficiency Virus–Infected Patients
Author(s) -
Thira Sirisanthana,
Khuanchai Supparatpinyo,
Joseph H. Perriëns,
Kenrad E. Nelson
Publication year - 1998
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/520280
Subject(s) - penicillium marneffei , amphotericin b , itraconazole , medicine , adverse effect , opportunistic infection , mycosis , regimen , sida , aids related opportunistic infections , virology , human immunodeficiency virus (hiv) , immunology , microbiology and biotechnology , viral disease , dermatology , antifungal , biology , coinfection
Disseminated infection with Penicillium marneffei is common in patients infected with human immunodeficiency virus (HIV) in Southeast Asia. Treatment with amphotericin B alone is effective but requires a prolonged hospital stay. We conducted an open-label nonrandomized study to evaluate the efficacy and safety of treatment with amphotericin B at a dosage of 0.6 mg/(kg.d) intraveneously for 2 weeks, followed by a 400-mg/d dosage of oral itraconazole for 10 weeks. Of the 74 HIV-infected patients we studied who had disseminated P. marneffei infection, diagnosed by positive fungal culture and clinical evidence of infection, 72 (97.3%) responded to the treatment. There were no serious adverse drug effects. It was concluded that the regimen was effective and safe for treatment of disseminated P. marneffei infection in HIV-infected patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom